Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus.

Münch S, Pigorsch SU, Devečka M, Dapper H, Feith M, Friess H, Weichert W, Jesinghaus M, Braren R, Combs SE, Habermehl D.

Radiat Oncol. 2019 Apr 16;14(1):66. doi: 10.1186/s13014-019-1270-8.

2.

Cellular Dissociation Grading Based on the Parameters Tumor Budding and Cell Nest Size in Pretherapeutic Biopsy Specimens Allows for Prognostic Patient Stratification in Esophageal Squamous Cell Carcinoma Independent From Clinical Staging.

Jesinghaus M, Brühl F, Steiger K, Klare P, Reiser M, Scheiter A, Konukiewitz B, Kuhn P, Münch S, Quante M, Schmid RM, Wilhelm D, Feith M, Friess H, Combs SE, Saur D, Boxberg M, Weichert W.

Am J Surg Pathol. 2019 May;43(5):618-627. doi: 10.1097/PAS.0000000000001230.

PMID:
30807302
3.

Influence of the surgical technique on survival in the treatment of carcinomas of the true cardia (Siewert Type II) - Right thoracoabdominal vs. transhiatal-abdominal approach.

Tosolini C, Reim D, Schirren R, Feith M, Friess H, Novotny AR.

Eur J Surg Oncol. 2019 Mar;45(3):416-424. doi: 10.1016/j.ejso.2018.09.017. Epub 2018 Oct 17.

PMID:
30396809
4.

A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas.

Adams O, Janser FA, Dislich B, Berezowska S, Humbert M, Seiler CA, Kroell D, Slotta-Huspenina J, Feith M, Ott K, Tschan MP, Langer R.

PLoS One. 2018 Jun 13;13(6):e0197610. doi: 10.1371/journal.pone.0197610. eCollection 2018.

5.

Correction to: MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus.

Slotta-Huspenina J, Drecoll E, Feith M, Habermehl D, Combs SE, Weichert W, Bettstetter M, Becker K, Langer R.

J Transl Med. 2018 May 16;16(1):128. doi: 10.1186/s12967-018-1513-8.

6.

MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus.

Slotta-Huspenina J, Drecoll E, Feith M, Habermehl D, Combs S, Weichert W, Bettstetter M, Becker K, Langer R.

J Transl Med. 2018 Apr 25;16(1):109. doi: 10.1186/s12967-018-1492-9. Erratum in: J Transl Med. 2018 May 16;16(1):128.

7.

Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma.

Spoerl S, Novotny A, Al-Batran SE, Lordick F, Thuss-Patience P, Pauligk C, Haller B, Feith M, Lorenzen S.

Eur J Cancer. 2018 Feb;90:26-33. doi: 10.1016/j.ejca.2017.11.020. Epub 2017 Dec 20.

PMID:
29272782
8.

Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus.

Münch S, Pigorsch SU, Feith M, Slotta-Huspenina J, Weichert W, Friess H, Combs SE, Habermehl D.

Radiat Oncol. 2017 Nov 21;12(1):182. doi: 10.1186/s13014-017-0904-y.

9.

Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.

Jesinghaus M, Steiger K, Slotta-Huspenina J, Drecoll E, Pfarr N, Meyer P, Konukiewitz B, Bettstetter M, Wieczorek K, Ott K, Feith M, Langer R, Weichert W, Specht K, Boxberg M.

Oncotarget. 2017 Jul 18;8(29):46756-46768. doi: 10.18632/oncotarget.18606.

10.

A Novel Grading System Based on Tumor Budding and Cell Nest Size Is a Strong Predictor of Patient Outcome in Esophageal Squamous Cell Carcinoma.

Jesinghaus M, Boxberg M, Konukiewitz B, Slotta-Huspenina J, Schlitter AM, Steiger K, Specht K, Wieczorek K, Warth A, Schmidt T, Hartmann A, Demir IE, Feith M, Ott K, Weichert W.

Am J Surg Pathol. 2017 Aug;41(8):1112-1120. doi: 10.1097/PAS.0000000000000865.

PMID:
28505009
11.

Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT.

Münch S, Aichmeier S, Hapfelmeier A, Duma MN, Oechsner M, Feith M, Combs SE, Habermehl D.

Strahlenther Onkol. 2016 Oct;192(10):722-9. doi: 10.1007/s00066-016-1020-x. Epub 2016 Jul 14.

PMID:
27418129
12.

What to do after R1-resection of adenocarcinomas of the esophagogastric junction?

Gertler R, Richter J, Stecher L, Nitsche U, Feith M.

J Surg Oncol. 2016 Sep;114(4):428-33. doi: 10.1002/jso.24329. Epub 2016 Jun 22.

PMID:
27333949
13.

Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas.

Thies S, Guldener L, Slotta-Huspenina J, Zlobec I, Koelzer VH, Lugli A, Kröll D, Seiler CA, Feith M, Langer R.

Hum Pathol. 2016 Jun;52:1-8. doi: 10.1016/j.humpath.2016.01.016. Epub 2016 Feb 10.

PMID:
26980046
14.

Prognostic significance of the tumour-adjacent tissue in head and neck cancers.

Raudenska M, Sztalmachova M, Gumulec J, Fojtu M, Polanska H, Balvan J, Feith M, Binkova H, Horakova Z, Kostrica R, Kizek R, Masarik M.

Tumour Biol. 2015 Dec;36(12):9929-39. doi: 10.1007/s13277-015-3755-x. Epub 2015 Jul 14.

PMID:
26168959
15.

Influence of an elevated nutrition risk score (NRS) on survival in patients following gastrectomy for gastric cancer.

Bachmann J, Müller T, Schröder A, Riediger C, Feith M, Reim D, Friess H, Martignoni ME.

Med Oncol. 2015 Jul;32(7):204. doi: 10.1007/s12032-015-0631-x. Epub 2015 Jun 13.

PMID:
26071123
16.

The impact of neural invasion severity in gastrointestinal malignancies: a clinicopathological study.

Liebl F, Demir IE, Mayer K, Schuster T, DʼHaese JG, Becker K, Langer R, Bergmann F, Wang K, Rosenberg R, Novotny AR, Feith M, Reim D, Friess H, Ceyhan GO.

Ann Surg. 2014 Nov;260(5):900-7; discussion 907-8. doi: 10.1097/SLA.0000000000000968.

17.

Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.

Aichler M, Motschmann M, Jütting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR, Walch A.

Oncotarget. 2014 Aug 30;5(16):6620-32.

18.

Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.

Karamitopoulou E, Thies S, Zlobec I, Ott K, Feith M, Slotta-Huspenina J, Lordick F, Becker K, Langer R.

Am J Surg Pathol. 2014 Nov;38(11):1551-6. doi: 10.1097/PAS.0000000000000255.

19.

Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus.

Slotta-Huspenina J, Becker KF, Feith M, Walch A, Langer R.

Cancers (Basel). 2014 Jun 27;6(3):1382-93. doi: 10.3390/cancers6031382.

20.

Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma.

Gertler R, Siveke JT, Feith M.

J Clin Oncol. 2014 Jul 1;32(19):2112. doi: 10.1200/JCO.2013.54.7398. Epub 2014 May 27. No abstract available.

PMID:
24868019
21.

Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade.

Geppert CI, Rümmele P, Sarbia M, Langer R, Feith M, Morrison L, Pestova E, Schneider-Stock R, Hartmann A, Rau TT.

Br J Cancer. 2014 Jun 10;110(12):2985-95. doi: 10.1038/bjc.2014.238. Epub 2014 May 22.

22.

Perivascular epitheloid cell tumor (PEComa) mimicking retroperitoneal liposarcoma.

Wildgruber M, Becker K, Feith M, Gaa J.

World J Surg Oncol. 2014 Jan 6;12:3. doi: 10.1186/1477-7819-12-3.

23.

A multifactorial histopathologic score for the prediction of prognosis of resected esophageal adenocarcinomas after neoadjuvant chemotherapy.

Langer R, Becker K, Zlobec I, Gertler R, Sisic L, Büchler M, Lordick F, Slotta-Huspenina J, Weichert W, Höfler H, Feith M, Ott K.

Ann Surg Oncol. 2014 Mar;21(3):915-21. doi: 10.1245/s10434-013-3410-y. Epub 2013 Nov 27.

PMID:
24281419
24.

Prevalence and topography of lymph node metastases in early esophageal and gastric cancer.

Gertler R, Stein HJ, Schuster T, Rondak IC, Höfler H, Feith M.

Ann Surg. 2014 Jan;259(1):96-101. doi: 10.1097/SLA.0000000000000239.

PMID:
24096772
25.

A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas.

Slotta-Huspenina J, Wolff C, Drecoll E, Feith M, Bettstetter M, Malinowsky K, Bauer L, Becker K, Ott K, Höfler H, Becker KF, Langer R.

Br J Cancer. 2013 Jul 23;109(2):370-8. doi: 10.1038/bjc.2013.319. Epub 2013 Jul 9.

26.

Chylothorax after esophagectomy for cancer: impact of the surgical approach and neoadjuvant treatment: systematic review and institutional analysis.

Kranzfelder M, Gertler R, Hapfelmeier A, Friess H, Feith M.

Surg Endosc. 2013 Oct;27(10):3530-8. doi: 10.1007/s00464-013-2991-7. Epub 2013 May 25. Review.

PMID:
23708712
27.

Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria.

Aichler M, Elsner M, Ludyga N, Feuchtinger A, Zangen V, Maier SK, Balluff B, Schöne C, Hierber L, Braselmann H, Meding S, Rauser S, Zischka H, Aubele M, Schmitt M, Feith M, Hauck SM, Ueffing M, Langer R, Kuster B, Zitzelsberger H, Höfler H, Walch AK.

J Pathol. 2013 Aug;230(4):410-9. doi: 10.1002/path.4199.

PMID:
23592244
28.

Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.

Bettstetter M, Berezowska S, Keller G, Walch A, Feuchtinger A, Slotta-Huspenina J, Feith M, Drecoll E, Höfler H, Langer R.

Hum Pathol. 2013 May;44(5):829-36. doi: 10.1016/j.humpath.2012.08.005. Epub 2012 Nov 14.

PMID:
23158210
29.

Evidence of prognostic relevant expression profiles of heat-shock proteins and glucose-regulated proteins in oesophageal adenocarcinomas.

Slotta-Huspenina J, Berg D, Bauer K, Wolff C, Malinowsky K, Bauer L, Drecoll E, Bettstetter M, Feith M, Walch A, Höfler H, Becker KF, Langer R.

PLoS One. 2012;7(7):e41420. doi: 10.1371/journal.pone.0041420. Epub 2012 Jul 24.

30.

The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging.

Schauer MC, Stoecklein NH, Theisen J, Kröpil F, Baldus S, Hoelscher A, Feith M, Bölke E, Matuschek C, Budach W, Knoefel WT.

Eur J Med Res. 2012 May 14;17:10. doi: 10.1186/2047-783X-17-10.

31.

Management of ERCP-related small bowel perforations: the pivotal role of physical investigation.

Dubecz A, Ottmann J, Schweigert M, Stadlhuber RJ, Feith M, Wiessner V, Muschweck H, Stein HJ.

Can J Surg. 2012 Apr;55(2):99-104. doi: 10.1503/cjs.027110.

32.

Bile acids down-regulate caveolin-1 in esophageal epithelial cells through sterol responsive element-binding protein.

Prade E, Tobiasch M, Hitkova I, Schäffer I, Lian F, Xing X, Tänzer M, Rauser S, Walch A, Feith M, Post S, Röcken C, Schmid RM, Ebert MP, Burgermeister E.

Mol Endocrinol. 2012 May;26(5):819-32. doi: 10.1210/me.2011-1140. Epub 2012 Apr 3.

33.

MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma.

Elsner M, Rauser S, Maier S, Schöne C, Balluff B, Meding S, Jung G, Nipp M, Sarioglu H, Maccarrone G, Aichler M, Feuchtinger A, Langer R, Jütting U, Feith M, Küster B, Ueffing M, Zitzelsberger H, Höfler H, Walch A.

J Proteomics. 2012 Aug 3;75(15):4693-704. doi: 10.1016/j.jprot.2012.02.012. Epub 2012 Feb 17.

PMID:
22365974
34.

Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging.

Meding S, Nitsche U, Balluff B, Elsner M, Rauser S, Schöne C, Nipp M, Maak M, Feith M, Ebert MP, Friess H, Langer R, Höfler H, Zitzelsberger H, Rosenberg R, Walch A.

J Proteome Res. 2012 Mar 2;11(3):1996-2003. doi: 10.1021/pr200784p. Epub 2012 Feb 3.

PMID:
22224404
35.

Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis.

Dubecz A, Gall I, Solymosi N, Schweigert M, Peters JH, Feith M, Stein HJ.

J Thorac Oncol. 2012 Feb;7(2):443-7. doi: 10.1097/JTO.0b013e3182397751.

36.

Cholecystectomy in the very elderly--is 90 the new 70?

Dubecz A, Langer M, Stadlhuber RJ, Schweigert M, Solymosi N, Feith M, Stein HJ.

J Gastrointest Surg. 2012 Feb;16(2):282-5. doi: 10.1007/s11605-011-1708-2. Epub 2011 Dec 6.

PMID:
22143419
37.

[The new TNM classification of tumors of the esophagogastric junction. Surgical consequences].

Schuhmacher C, Novotny A, Feith M, Friess H.

Chirurg. 2012 Jan;83(1):23-30. doi: 10.1007/s00104-011-2146-0. Review. German.

PMID:
22090018
38.

Discovery of new molecular subtypes in oesophageal adenocarcinoma.

Berg D, Wolff C, Langer R, Schuster T, Feith M, Slotta-Huspenina J, Malinowsky K, Becker KF.

PLoS One. 2011;6(9):e23985. doi: 10.1371/journal.pone.0023985. Epub 2011 Sep 23.

39.

Barrett's esophagus: treatments of adenocarcinomas II.

Twaddell WS, Wu PC, Verhage RJ, Feith M, Ilson DH, Schuhmacher CP, Luketich JD, Brücher B, Vallböhmer D, Hofstetter WL, Krasna MJ, Kandioler D, Schneider PM, Wijnhoven BP, Sontag SJ.

Ann N Y Acad Sci. 2011 Sep;1232:265-91. doi: 10.1111/j.1749-6632.2011.06056.x.

PMID:
21950818
40.

Barrett's esophagus: treatments of adenocarcinomas I.

Komanduri S, Deprez PH, Atasoy A, Hofmann G, Pokieser P, Ba-Ssalamah A, Collard JM, Wijnhoven BP, Verhage RJ, Brücher B, Schuhmacher C, Feith M, Stein H.

Ann N Y Acad Sci. 2011 Sep;1232:248-64. doi: 10.1111/j.1749-6632.2011.06055.x.

PMID:
21950817
41.

How to classify adenocarcinomas of the esophagogastric junction: as esophageal or gastric cancer?

Gertler R, Stein HJ, Loos M, Langer R, Friess H, Feith M.

Am J Surg Pathol. 2011 Oct;35(10):1512-22. doi: 10.1097/PAS.0b013e3182294764.

PMID:
21934477
42.

Training of a standardized natural orifice transluminal endoscopic surgery cholecystectomy using an ex vivo training unit.

Gillen S, Fiolka A, Kranzfelder M, Wolf P, Feith M, Schneider A, Meining A, Friess H, Feussner H.

Endoscopy. 2011 Oct;43(10):876-81. doi: 10.1055/s-0030-1256556. Epub 2011 Aug 10.

PMID:
21833898
43.

Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.

Langer R, Rauser S, Feith M, Nährig JM, Feuchtinger A, Friess H, Höfler H, Walch A.

Mod Pathol. 2011 Jul;24(7):908-16. doi: 10.1038/modpathol.2011.52. Epub 2011 Apr 22.

44.

Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system.

Gertler R, Stein HJ, Langer R, Nettelmann M, Schuster T, Hoefler H, Siewert JR, Feith M.

Ann Surg. 2011 Apr;253(4):689-98. doi: 10.1097/SLA.0b013e31821111b5.

PMID:
21475008
45.

Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma.

Loos M, Langer R, Schuster T, Gertler R, Walch A, Rauser S, Friess H, Feith M.

Ann Thorac Surg. 2011 Apr;91(4):1025-31. doi: 10.1016/j.athoracsur.2010.12.041.

PMID:
21440117
46.

Healing occurs in most patients that receive endoscopic stents for anastomotic leakage; dislocation remains a problem.

Feith M, Gillen S, Schuster T, Theisen J, Friess H, Gertler R.

Clin Gastroenterol Hepatol. 2011 Mar;9(3):202-10. doi: 10.1016/j.cgh.2010.12.010. Epub 2010 Dec 17.

PMID:
21172455
47.

Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases.

Langer R, Becker K, Feith M, Friess H, Höfler H, Keller G.

Mod Pathol. 2011 Apr;24(4):495-501. doi: 10.1038/modpathol.2010.220. Epub 2010 Dec 3.

48.

Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier.

Balluff B, Elsner M, Kowarsch A, Rauser S, Meding S, Schuhmacher C, Feith M, Herrmann K, Röcken C, Schmid RM, Höfler H, Walch A, Ebert MP.

J Proteome Res. 2010 Dec 3;9(12):6317-22. doi: 10.1021/pr100573s. Epub 2010 Nov 8.

PMID:
21058730
49.

High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma.

Rauser S, Langer R, Tschernitz S, Gais P, Jütting U, Feith M, Höfler H, Walch A.

BMC Cancer. 2010 Nov 5;10:608. doi: 10.1186/1471-2407-10-608.

50.

Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study.

Langer R, Mutze K, Becker K, Feith M, Ott K, Höfler H, Keller G.

J Clin Pathol. 2010 Nov;63(11):994-8. doi: 10.1136/jcp.2010.080952. Epub 2010 Oct 5.

PMID:
20924032

Supplemental Content

Support Center